◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...
Customize Items

Monte Rosa Therapeutics, Inc.

CIK: 1826457 SIC: 2836
$123.67M
Revenue
$-38.63M
Net Income
-
Gross Margin
-43.83%
Op. Margin
$-158.07M
Free Cash Flow
Financial Statements Annual (10-K)
Showing 5 of 5 annual reports available (2021 - 2025)
Breakdown TTM
(Dec 31, 2025)
FY 2025
(Dec 31, 2025)
FY 2024
(Dec 31, 2024)
FY 2023
(Dec 31, 2023)
FY 2022
(Dec 31, 2022)
FY 2021
(Dec 31, 2021)
+ Total Revenue $123.67M $123.67M $75.62M - - -
Revenue Growth % 0.0% 63.5% nan% nan% nan% nan%
Operating Expenses $177.88M $177.88M $156.73M $143.31M $112.38M $72.88M
Research & Development $141.50M $141.50M $121.56M $111.27M $85.06M $57.16M
+ Operating Income $-54.21M $-54.21M $-81.11M $-143.31M $-112.38M $-72.88M
Operating Margin % -43.8% -43.8% -107.3% nan% nan% nan%
Other Income/Expense $14.48M $14.48M $10.98M $8.30M $3.88M $-1.08M
Income Before Tax $-39.72M $-39.72M $-70.13M $-135.01M $-108.50M -
Income Tax Expense $-1.10M $-1.10M $2.57M $338.00K - -
+ Net Income $-38.63M $-38.63M $-72.70M $-135.35M $-108.50M $-73.96M
Net Margin % -31.2% -31.2% -96.1% nan% nan% nan%
Basic Shares Outstanding 826K 83.1M 73.9M 51.4M 47.2M 25.0M
Diluted Shares Outstanding 128K 83.1M 73.9M 51.4M 47.2M 25.0M
Breakdown FY 2025
(Dec 31, 2025)
FY 2024
(Dec 31, 2024)
FY 2023
(Dec 31, 2023)
FY 2022
(Dec 31, 2022)
FY 2021
(Dec 31, 2021)
Cash & Cash Equivalents $129.88M $224.25M $128.10M $54.91M $346.07M
Other Current Assets $4.48M $5.12M $3.29M $4.44M $2.60M
Total Current Assets $393.19M $377.44M $236.21M $275.89M $348.67M
Property Plant & Equipment $25.99M $29.48M $33.80M $27.07M $12.32M
Other Non-current Assets $148.00K $115.00K $352.00K $278.00K -
Total Assets $448.66M $438.73M $303.75M $342.39M $366.33M
Accounts Payable $3.55M $17.21M $11.15M $7.86M $6.56M
Accrued Liabilities $26.69M $18.79M - - -
Deferred Revenue $29.57M $117.23M $17.68M - -
Total Current Liabilities $64.21M $156.95M $46.59M $25.57M $16.64M
Total Liabilities $215.60M $215.80M $124.50M $70.98M $18.81M
Common Stock $7.00K $6.00K $5.00K $5.00K $5.00K
Retained Earnings $-477.21M $-438.59M $-365.89M $-230.54M $-122.03M
Total Stockholders Equity $233.06M $222.94M $179.25M $271.41M $347.51M
Total Liabilities & Equity $448.66M $438.73M $303.75M $342.39M $366.33M
Breakdown TTM
(Dec 31, 2025)
FY 2025
(Dec 31, 2025)
FY 2024
(Dec 31, 2024)
FY 2023
(Dec 31, 2023)
FY 2022
(Dec 31, 2022)
FY 2021
(Dec 31, 2021)
Net Income $-38.63M $-38.63M $-72.70M $-135.35M $-108.50M $-73.96M
Stock-based Compensation $34.35M $18.86M $18.13M $16.67M $11.66M $5.20M
Change in Payables $-36.56M $-13.71M $6.25M $5.76M $-744.00K $-706.00K
Operating Cash Flow $-148.50M $-22.80M $42.00M $-43.80M $-92.47M $-59.36M
Capital Expenditure $9.57M $4.70M $3.99M $19.04M $12.91M $9.73M
Purchases of Investments $671.74M $376.68M $230.36M $103.15M $384.42M -
Investing Cash Flow $-276.97M $-101.83M $-44.45M $88.80M $-219.22M $-9.65M
Stock Issued - - - - $20.05M -
Dividends Paid - - - - - -
Financing Cash Flow $30.74M $30.35M $98.89M $27.49M $20.47M $377.56M
Net Change in Cash $-394.73M $-94.28M $96.44M $72.49M $-291.22M $308.55M
SEC Filing Format - Data shown as it appears in the Q3 2025 (10-Q) filing Period ended: Sep 30, 2025
Condensed Consolidated Statements of Operations
Description Sep 30, 2025 Sep 30, 2025
Current Prior Year Current YTD Prior Year YTD
Total Revenue $12.77M - $120.89M -
Operating Expenses $45.74M - $125.38M -
Research & Development $36.68M - $99.52M -
Operating Income $-32.98M - $-4.49M -
Other Income/Expense $2.72M - $10.85M -
Income Before Tax $-30.26M - $6.35M -
Income Tax Expense $-3.18M - $-1.16M -
Net Income $-27.08M $-30.31M $7.51M -
Basic Shares Outstanding $82.40M - $82.25M -
Diluted Shares Outstanding $82.40M - $82.94M -
Condensed Consolidated Balance Sheets
Description Sep 30, 2025 Dec 31, 2024
Cash & Cash Equivalents $208.34M $224.25M
Other Current Assets $5.59M $5.12M
Total Current Assets $401.82M $377.44M
Property Plant & Equipment $27.60M $29.48M
Other Non-current Assets $411.00K $115.00K
Total Assets $459.84M $438.73M
Accounts Payable $14.51M $17.21M
Deferred Revenue $24.79M $117.23M
Total Current Liabilities $61.44M $156.95M
Total Liabilities $214.00M $215.80M
Common Stock $6.00K $6.00K
Retained Earnings $-431.08M $-438.59M
Total Stockholders Equity $245.84M $222.94M
Total Liabilities & Equity $459.84M $438.73M
Condensed Consolidated Statements of Cash Flows
Description Sep 30, 2025 Sep 30, 2025
Current Prior Year Current YTD Prior Year YTD
Net Income $-27.08M $-30.31M $7.51M -
Stock-based Compensation - - $14.56M -
Change in Payables - - $-3.10M -
Operating Cash Flow - - $20.22M -
Capital Expenditure - - $3.93M -
Purchases of Investments - - $223.02M -
Investing Cash Flow - - $-36.77M -
Stock Issued - - - -
Financing Cash Flow - - $727.00K -
Net Change in Cash - - $-15.82M -

All values are in USD (United States Dollars). Data is sourced from SEC EDGAR 10-K filings.

Annual data represents full fiscal year results. FY = Fiscal Year ending.

NEWS
Loading article...
NEWS
Loading news...
TRENDING
Loading...